POSTSTROKE SPASTICITY: AN INDIVIDUALIZED APPROACH TO TREATMENT
Abstract
Poststroke spasticity is common in many patients and frequently hampers the recovery of lost motor functions. Therapeutic exercises and a gradual increase in motion loads and social and daily living activities play a leading role in the treatment of spasticity. Botulinium toxin type A is recognized to offer a highly effective and safe treatment for poststroke spasticity, as confirmed by clinical trials conducted in accordance with the principles of evidence-based medicine. The application of a personalized poststroke rehabilitation program permits the maximum result to be achieved in a considerable number of patients. The paper reviews the literature on spasticity and a clinical case that demonstrates an individual approach to treating poststroke spasticity.
About the Author
V. A. Tolmacheva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Violetta Aleksandrovna Tolmacheva - Department of Nervous System Diseases and Neurosurgery.
11, Rossolimo St., Moscow 119021, vtolmacheva@yandex.ru
References
1. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.
2. Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 328 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 328 p.]
3. Епифанов ВА, Епифанов АВ. Реабилитация больных, перенесших инсульт. Москва: МЕДпресс-информ; 2013. 243 с. [Epifanov VA, Epifanov AV. Reabilitatsiya bol'nykh, perenesshikh insul't [Rehabilitation of patients with stroke]. Moscow: MEDpressinform; 2013. 243 p.]
4. Скворцова ВИ, Губский ЛВ, Стаховская ЛВ и др. Ишемический инсульт. В кн.: Гусев ЕИ, Коновалов АИ, Скворцова ВИ, редакторы. Неврология, национальное руководство. Москва: Гэотар-медиа; 2009. С. 592-615. [Skvortsova VI, Gubskii LV, Stakhovskaya LV, et al. Ischemic stroke. In: Gusev EI, Konovalov AI, Skvortsova VI, editors. Nevrologiya, natsional'noe rukovodstvo [Neurology. A national guide]. Moscow: Geotar-media; 2009. P. 592-615.]
5. Парфенов ВА. Спастичность. В кн.: Орлова ОР, Яхно НН, редакторы. Применение ботокса (токсина ботулизма типа А)ив клинической практике: руководство дляиврачей. Москва: Каталог; 2001. С. 91-122. [Parfenov VA. Spasticity. In: Orlova OR, Yakhno NN, editors. Primenenie botoksa (toksina botulizma tipa A) v klinicheskoi praktike:иrukovodstvo dlya vrachei [The use of Botoxи(botulinum toxin type A) in clinical practice: a guide for physicians]. Moscow: Katalog; 2001. P. 91-122.]
6. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]
7. Кадыков АС, Черникова ЛА, Шахпаронова НВ. Реабилитация неврологических больных. Москва: МЕДпресс-информ; 2015. 560 с. [Kadykov AS, Chernikova LA, Shakhparonova NV. Reabilitatsiya nevrologicheskikh bol'nykh [Rehabilitation of neurological patients]. Moscow: MEDpress-inform; 2015. 560 p.]
8. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve. Suppl. 1997;6:S1-13.
9. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 May;31(5):552-71.
10. Lance JW. Symposium synopsis, in Spasticity: Disordered Motor Control., Feldman RG, Young RR, Koella WP, Editors. Chicago: Year Book Medical Publishers; 1980. P. 485–94.
11. Завалишин ИА. Спастичность. Русский медицинский журнал. 2004;(5):261-6. [Zavalishin IA. Spasticity. Russkii meditsinskii zhurnal. 2004;(5):261-6. (In Russ.)].
12. Райхель Г. Терапевтическое руководство спастичность – дистонии. 1-е изд. Бремен: УНИ-МЕД; 2013. C. 12–3. [Raikhel' G. Terapevticheskoe rukovodstvo spastichnost' – distonii [Therapeutic guide spasticity – dystonia]. 1st ed. Bremen: UNI-MED; 2013. P. 12–3.]
13. Парфенов ВА. Патогенез и лечение спастичности. Русский медицинский журнал. 2001;(25):1170-4. [Parfenov VA. Pathogenesis and treatment of spasticity. Russkii meditsinskii zhurnal. 2001;(25):1170-4. (In Russ.)].
14. Парфенов ВА. Постинсультная спастичность. Лечащий врач. 2008;(5):34–8. [Parfenov VA. Postinsul'tnaya spastichnost' [Post-stroke spasticity]. Lechashchii vrach. 2008;(5):34–8. (In Russ.)].
15. Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005 May;31(5):535-51.
16. Катушкина ЭА, Зиновьева ОЕ, Яхно НН и др. Постинсультная спастичность: нейрофизиологические характеристики состояния верхнего и нижнего мотонейронов. Неврологический журнал. 2011;16(4):11–8. [Katushkina EA, Zinov'eva OE, Yakhno NN, et al. Post-stroke spasticity: neurophysiologic features of state of upper and lower motoneurons. Nevrologicheskii zhurnal. 2011;16(4):11–8. (In Russ.)].
17. Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1355-9.
18. Urban PP, Wolf T, Uebele M, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010 Sep;41(9):2016-20. doi: 10.1161/STROKEHA.110.581991. Epub 2010 Aug 12.
19. Lundströ m E, Smits A, Terent A, Borg J. Time-course and determinants of spasticity during the first six month following first-ever stroke. J Rehabil Med. 2010 Apr;42(4):296-301. doi: 10.2340/16501977-0509.
20. Wissel J, Schelosky LD, Scott J, et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010 Jul;257(7):1067-72. doi: 10.1007/s00415-010-5463-1. Epub 2010 Feb 6.
21. Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004 Jan;35(1):134-9. Epub 2003 Dec 18.
22. Хатькова СЕ, Орлова ОР, Тимербаева СЛ. Оценка клинического профиля взрослых пациентов со спастичностью верхней конечности, которым показаны инъекции ботулинического токсина типа А (по данным международного исследования). Журнал неврологии и психиатрии им. С.С.Корсакова. 2011;(8):23–6. [Khat'kova SE, Orlova OR, Timerbaeva SL. Assessment of the clinical profile of adult patients with spasticity of the upper limb, which shows the injection of botulinum toxin type A (according to international survey). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2011;(8):23-6. (In Russ.)].
23. Bakheit AM, Zakine B, Maisonobe P, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type a: an international survey. Int J Rehabil Res. 2010 Sep;33(3):199-204. doi: 10.1097/MRR.0b013e328332f5e0.
24. Wissel J, Verrier M, Simpson DM, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R. 2015 Jan;7(1):60-7. doi: 10.1016/j.pmrj.2014.08.946. Epub 2014 Aug 27.
25. Francisco GE, McGuire JR. Poststroke spasticity management. Stroke. 2012 Nov;43(11):3132-6. doi: 10.1161/STROKEAHA.111.639831. Epub 2012 Sep 13.
26. Rosales RL, Kong KH, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012 Sep;26(7): 812-21. doi: 10.1177/1545968311430824. Epub 2012 Feb 27.
27. Данилов АБ, Давыдов ОС. Центральная нейропатическая боль: клинико-диагностические аспекты и возможности терапии на основе доказательств. Неврология и ревматология. 2009;(1):60-4. [Danilov AB, Davydov OS. Central neuropathic pain: clinical and diagnostic aspects and therapeutic options based on evidence. Nevrologiya i revmatologiya. 2009;(1): 60-4. (In Russ.)].
28. Bakheit M. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse; 2007. 216 p.
29. Ward AB. Handbook of the management of adult spasticity course. Stoke on Trent; 2008. 264 p.
30. Elovic E, Brashear A. Spasticity: Diagnosis and Management. 1st ed. Demos Medical Publishing; 2010. 412 p.
31. Barnes MP, Johnson GR. UMN syndrome and spasticity. Cambridge University Press; 2008.
32. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19): 1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.
33. Autti-Ramo J, Larsen T, Peltonen J. The use of botulinum toxin treatment in children with movement disorders. Eur J Neurol. 2007;(4):23-6.
34. Royal M. The use of botulinum toxin in the management of myofascial pain and other conditions associated with painful muscle spasm. In: Brin M, Jankovic J, Hallet M, editors. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. 204 p.
35. Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010 Dec;32(14): 2282-303. doi: 10.1016/j.clinthera.2011.01.005.
36. Foley N, Murie-Fernandez M, Speechley M, et al. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur J Neurol. 2010 Dec;17(12): 1419-27. doi: 10.1111/j.1468-1331.2010.03084.x.
37. Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010 Aug; 257(8):1330-7. doi: 10.1007/s00415-010-5526-3. Epub 2010 Apr 1.
38. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15(4):289-300.
39. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of poststroke lower limb spasticity: a prospective openlabel study. Eur J Phys Rehabil Med. 2013 Aug;49(4):483-9. Epub 2013 Mar 13.
40. Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexina proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna). 2013 Mar;120(3):469-76. doi: 10.1007/s00702-012-0892-x. Epub 2012 Sep 7.
Review
For citations:
Tolmacheva V.A. POSTSTROKE SPASTICITY: AN INDIVIDUALIZED APPROACH TO TREATMENT. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):71-76. (In Russ.) https://doi.org/10.14412/2074-2711-2016-4-71-76
Views: 654
Email this article 